Multiple effects of pentyl-4-yn-VPA enantiomers: From toxicity to short-term memory enhancement

Neuropharmacology

Volumn 52, Issue 3, 2007, Pages 764-778

  Gotfryd, Kamil ^a   Owczarek, Sylwia ^a   Hoffmann, Katrin ^b   Klementiev, Boris ^c   Nau, Heinz ^b   Berezin, Vladimir ^a   Bock, Elisabeth ^a   Walmod, Peter S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c Enkam Pharmaceuticals AS   (Denmark)

Author keywords

Memory; Neuritogenesis; Pentyl 4 yn VPA; Synaptic maturation; Teratogen; Tumor suppression

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENTYL 4 PENTYNOIC ACID; PROTEIN KINASE B; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CEREBELLUM; CONTROLLED STUDY; DRUG EFFECT; ENANTIOMER; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULE CELL; MALE; NERVE CELL CULTURE; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; SYNAPSE; TERATOGENICITY; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CELL MOVEMENT; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MEMORY, SHORT-TERM; MICE; NEURITES; NEURONS; RATS; RATS, WISTAR; STEREOISOMERISM; SYNAPSES; SYNAPTOPHYSIN; TIME FACTORS; VALPROIC ACID;

EID: 33846861324     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.09.017     Document Type: Article

References (42)

1. Blaheta R.A., and Cinatl Jr. J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 22 (2002) 492-511
2. Blaheta R.A., Michaelis M., Driever P.H., and Cinatl Jr. J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 25 (2005) 383-397
3. Bacon C.L., Berezin V., Bode G., Bock E., Bojic U., Doherty P., Ehlers K., Ellerbeck U., Julien P., Kawa A., Maar T.E., Nau H., Pirovano R., Regan C.M., Schousboe A., Spezia F., Walsh F.S., and Williams E.J. Cell proliferation, migration and CAM-dependent neurite outgrowth as developmental in vitro endpoints for screening teratogenic potential: application to valproic acid and related analogues of varying potency. Toxicol. In vitro 12 (1998) 101-109
4. Bojic U., Ehlers K., Ellerbeck U., Bacon C.L., O'Driscoll E., O'Connell C., Berezin V., Kawa A., Lepekhin E., Bock E., Regan C.M., and Nau H. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. Eur. J. Pharmacol. 354 (1998) 289-299
5. D'Mello S.R., Galli C., Ciotti T., and Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl Acad. Sci. U.S.A. 90 (1993) 10989-10993
6. Ditlevsen D.K., Køhler L.B., Pedersen M.V., Risell M., Kolkova K., Meyer M., Berezin V., and Bock E. The role of phosphatidylinositol 3-kinase in neural cell adhesion molecule- mediated neuronal differentiation and survival. J. Neurochem. 84 (2003) 546-556
7. Eickholt B.J., Towers G.J., Ryves W.J., Eikel D., Adley K., Ylinen L.M., Chadborn N.H., Harwood A.J., Nau H., and Williams R.S. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3β inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol. Pharmacol. 67 (2005) 1426-1433
8. Eikel D., Lampen A., and Nau H. Teratogenic Effects Mediated by Inhibition of Histone Deacetylases: Evidence from Quantitative Structure Activity Relationships of 20 Valproic Acid Derivatives. Chem. Res. Toxicol. 19 (2006) 272-278
9. Eikel D., Hoffmann K., Zoll K., Lampen A., and Nau H. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite S-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mice model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further VPA hydroxamates and amides. Drug Metab. Dispos. 34 (2006) 612-620
10. Ferguson J.N., Young L.J., and Insel T.R. The neuroendocrine basis of social recognition. Front. Neuroendocrinol. 23 (2002) 200-224
11. Foley A.G., Gallagher H.C., Murphy K.J., and Regan C.M. Pentyl-4-yn-valproic acid reverses age-associated memory impairment in the Wistar rat. Neurobiol. Aging 25 (2004) 539-546
12. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
13. Isoherranen N., Yagen B., and Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. Curr. Opin. Neurol. 16 (2003) 203-211
14. Jin N., Kovács A.D., Sui Z., Dewhurst S., and Maggirwar S.B. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48 (2005) 576-583
15. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37 (2000) 103-110
16. Kasper C., Stahlhut M., Berezin V., Maar T.E., Edvardsen K., Kiselyov V.V., Soroka V., and Bock E. Functional characterization of NCAM fibronectin type III domains: demonstration of modulatory effects of the proline-rich sequence encoded by alternatively spliced exons a and AAG. J. Neurosci. Res. 46 (1996) 173-186
17. Kogan J.H., Franland P.W., and Silva A.J. Long-term memory underlying hippocampus-dependent social recognition in mice. Hippocampus 10 (2000) 47-56
18. Kruman I., Bruce-Keller A.J., Bredesen D., Waeg G., and Mattson M.P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17 (1997) 5089-5100
19. Lampen A., Carlberg C., and Nau H. Peroxisome proliferator-activated receptor δ is a specific sensor for teratogenic valproic acid derivatives. Eur. J. Pharmacol. 431 (2001) 25-33
20. Lampen A., Grimaldi P.A., and Nau H. Modulation of peroxisome proliferator-activated receptor δ activity affects neural cell adhesion molecule and polysialyltransferase ST8SiaIV induction by teratogenic valproic acid analogs in F9 cell differentiation. Mol. Pharmacol. 68 (2005) 193-203
21. Lindhout D., and Omtzigt J.G. Pregnancy and the risk of teratogenicity. Epilepsia 33 (1992) S41-S48
22. Loy R., and Tariot P.N. Neuroprotective properties of valproate. Potential benefit for AD and tauopathies. J. Mol. Neurosci. 19 (2002) 303-307
23. Maar T.E., Ronn L.C., Bock E., Berezin V., Moran J., Pasantes-Morales H., and Schousboe A. Characterization of microwell cultures of dissociated brain tissue for studies of cell-cell interactions. J. Neurosci. Res. 47 (1997) 163-172
24. Murphy K.J., Fox G.B., Foley A.G., Gallagher H.C., O'Connell A., Griffin A.M., Nau H., and Regan C.M. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J. Neurochem. 78 (2001) 704-714
25. Nau H., and Regan C.M. Antiproliferative and neurotrophic molecules. American Biogenetics Inc (1997) 08/298,108(5,672,746). 30-9-1997. USA Patent
26. Nau H., Zierer R., Spielmann H., Neubert D., and Gansau C. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci. 29 (1981) 2803-2814
27. Nau H., Hauck R.S., and Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69 (1991) 310-321
28. O'Loinsigh E.D., Gherardini L.M., Gallagher H.C., Foley A.G., Murphy K.J., and Regan C.M. Differential enantioselective effects of pentyl-4-yn-valproate on spatial learning in the rat, and neurite outgrowth and cyclin D3 expression in vitro. J. Neurochem. 88 (2004) 370-379
29. Perlman B.J., and Goldstein D.B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol. Pharmacol. 26 (1984) 83-89
30. Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
31. Regan C.M. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res. 347 (1985) 394-398
32. Rønn L.C., Ralets I., Hartz B.P., Bech M., Berezin A., Berezin V., Moller A., and Bock E. A simple procedure for quantification of neurite outgrowth based on stereological principles. J. Neurosci. Methods 100 (2000) 25-32
33. Skladchikova G., Berezin V., and Bock E. Valproic acid, but not its non-teratogenic analogue 2-isopropylpentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line N-Tera-2. Neurotoxicology 19 (1998) 357-370
34. Trojnar M.K., Wierzchowska-Cioch E., Krzyżanowski M., Jargiełło M., and Czuczwar S.J. New generation of valproic acid. Pol. J. Pharmacol. 56 (2004) 283-288
35. Versteeg H.H., Nijhuis E., van den Brink G.R., Evertzen M., Pynaert G.N., van Deventer S.J., Coffer P.J., and Peppelenbosch M.P. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem. J. 350 (2000) 717-722
36. Walmod P.S., Foley A., Berezin A., Ellerbeck U., Nau H., Bock E., and Berezin V. Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues. Cell Motil. Cytoskeleton 40 (1998) 220-237
37. Walmod P.S., Hartmann-Petersen R., Berezin A., Prag S., Kiselyov V.V., Berezin V., and Bock E. Evaluation of individual-cell motility. Methods Mol. Biol. 161 (2001) 59-83
38. Walmod P.S., Berezin A., Gallagher H.C., Gravemann U., Lepekhin E.A., Belman V., Bacon C.L., Nau H., Regan C.M., Berezin V., and Bock E. Automated in vitro screening of teratogens. Toxicol. Appl. Pharmacol. 181 (2002) 1-15
39. Walmod P.S., Gravemann U., Nau H., Berezin V., and Bock E. Discriminative power of an assay for automated in vitro screening of teratogens. Toxicol. In vitro 18 (2004) 511-525
40. Walmod P.S., Kolkova K., Berezin V., and Bock E. Zippers make signals: NCAM-mediated Molecular Interactions and Signal Transduction. Neurochem. Res. 29 (2004) 2015-2035
41. Williams R.S.B., Cheng L., Mudge A.W., and Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417 (2002) 292-295
42. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276 (2001) 31674-31683